All News
Safety of Combination Targeted Therapies in Psoriatic Arthritis
d
MedPage Today
Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased risk of serious infections, insurance claims data indicate.
Read Article
Rheums Speak: Future of Rheumatoid Arthritis
The third survey in this series addressed clinician views on future trends (AI), future therapies and lessons learned.
Read Article
Uncertainty with immunosuppressive for idiopathic inflammatory myopathies
A current Cochrane review suggests a continued unmet need regarding the status and utility of targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies (IIM). Overall there has been little progress since the previous Cochrane review (2012) that found little or no evidence to guide treatment.
Read Article
TNF Inhibitors in Takayasu's Arteritis
A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis.
Read Article
Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer
d
EurekAlert!
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for estrogen-responsive breast cancer, providing practical guidance for both osteoporosis specialists and oncologists.
Read Article
Clinical Rheumatology Thread for Busy GPs:
Post 1
Early inflammatory arthritis(IA): the 3–3–3 rule
•Onset ≤3 months
•Morning stiffness ≥30–60 minutes
•≥3 swollen joints (MCP/MTP common)
If present, manage as IA: urgent rheum referral; NSAIDs if no contraindications. https://t.co/hcoumX1ZVY
Aravind Palraj Rheumat_Aravind ( View Tweet)
TNF Inhibitors in Takayasu's Arteritis
A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis.
https://t.co/lJbvaYnylO https://t.co/uRBruhW2Fd
Dr. John Cush RheumNow ( View Tweet)
Tarsal Tunnel Syndrome: An Ultrasound Pictorial Review
https://t.co/Qr4ehZo41p
Tarsal tunnel syndrome (TTS) is an entrapment neuropathy caused by compression of the posterior tibial nerve or its branches as they pass beneath the flexor retinaculum at the medial ankle. Clinical https://t.co/FivPCl7EvU
Links:
sergio serrano belmar sserranobmsk ( View Tweet)
Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for https://t.co/ZkvToBBGdB
Dr. John Cush RheumNow ( View Tweet)
Detailed comprehensive overview of GLP-1RAs and SGLT2 inhibitors - their benefits w/ inflammatory conditions, & potential antiinflammatory effects. Bi-directional interplay between obesity, inflammation, and comorbid diseases https://t.co/oAQsuWVbZO https://t.co/SNqngATBtv
Dr. John Cush RheumNow ( View Tweet)
Rheumatic Dz & HIV
- Arthralgia: self limiting
- HIV-assoc arthritis: mimics RA
- Occurs w/ HIV: SpA, ReA, PsA
- Less : IIM, vasculitis, opportunistic infxn https://t.co/Yf7jZ0icZw https://t.co/6FuJgvDYRF
Links:
Dr. John Cush RheumNow ( View Tweet)
Medscape overview of Polymyositis has been updated - good click and learn! https://t.co/Utx389l7KP https://t.co/Nx9pPiBsMx
Links:
Dr. John Cush RheumNow ( View Tweet)
Cohort study of 1,553 Biologic or JAKi Rx IBD (Crohns; UC) pts (SpA excluded) found 106 (6.8%) w/ MSK Sxs & 30 (1.9%) later Dx w/ SpA (20: axial, 10: peripheral) after median F/U 5.2 yrs. SpA risk factors: partial Mayo UC (HR 1.57) & HLA-B27 positivity (HR 3.70) https://t.co/WgLLUjlLMk
Dr. John Cush RheumNow ( View Tweet)
The world of rheumatoid arthritis treatment has changed dramatically. What do the experts say about the evolution of biologics and DMARDs over the last 20 years?
Join us for a live webinar, moderated by Dr. Jack Cush, where we'll unpack the results of a nationwide survey.
Tues, https://t.co/pKhuHPwcs0
Dr. John Cush RheumNow ( View Tweet)
🧠 How well do you know this week’s rheumatology news?
The RheumIQ Weekly Quiz is LIVE!
✅ Test your knowledge
📈 Track your progress
🏆 Climb the leaderboard
🔗 Dive into the source materials
Take the quiz now ➡️ https://t.co/nCfbFLaVDx https://t.co/Dv4pD3Xd0b
Dr. John Cush RheumNow ( View Tweet)
Teaching You How to Think… (8.15.2025)
Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogren's trial, to PT or not to PT, and aphorisms to live by.
https://t.co/2MhzjNCUEW https://t.co/Mt9iEAYKsK
Dr. John Cush RheumNow ( View Tweet)
Glossary for Giant Cell Arteritis
Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international https://t.co/cIA3UvNcP6
Dr. John Cush RheumNow ( View Tweet)
JAMA overview of Obstructive sleep apnea (OSA) - affects 1 billion worldwide. Treatment options: Positive Airway Pressure, Oral Appliance, Positional Therapy, Weight Loss, upper airway surgery. https://t.co/imrdsLAocG https://t.co/JEneFvyijN
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves 1st new Fibromyalgia drug in 15 yrs - Tonmya (cyclobenzaprine HCl sublingual) as treatment of fibromyalgia in adults. Based on 2 phase 3 trials and 1400+ pts. Dose 2.8 mg tabs 1-2 SL qhs (peak concentration 4.3 hours; t1/2 life = 36 hrs, longer w/ elderly, liver dz) https://t.co/8DVRet5sjU
Dr. John Cush RheumNow ( View Tweet)
The Patient Journey with Rheumatic Disease
Oton and colleagues have reviewed the "patient journey" - from symptoms to specialty referral in those diagnosed with rheumatic and musculoskeletal diseases (RMDs). They identify the eight stages along the way and where improvements https://t.co/VY3kB3Ohmp
Dr. John Cush RheumNow ( View Tweet)
